VERTEX PHARMACEUTICALS INC (VRTX)

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

The biotech just added another potential growth driver to its pipeline.

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

The biotech just added another potential growth driver to its pipeline.

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Vertex just laid claim to an asset that might be very valuable.

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Vertex just laid claim to an asset that might be very valuable.

Could This Stock Be the Next Biotech Buyout?

Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.

Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review

The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.

Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock

Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.

Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts

An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack.

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Vertex Pharmaceuticals: Buy, Sell, or Hold?

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal

The companies expect the deal to close later this quarter.

Vertex to Buy Kidney Disease Drug Developer for $4.9 Billion

Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding the biotech company’s immune treatments to its growing pipeline.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

RSI Alert: Vertex Pharmaceuticals (VRTX) Now Oversold

Vertex to Announce First Quarter 2024 Financial Results on May 6

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?

This innovative machine rolls on.

3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April

These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

These companies are close to launching new products that could supercharge revenue.

Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul

These businesses are booming.

VRTX May 24th Options Begin Trading

Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

/CNW/ - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its New Drug Submission (NDS) for exagamglogene autotemcel (exa-cel) has been...

Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead

All three companies have very long runways for growth ahead.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Meet The "Magnificent Seven" of Healthcare Stocks

The tech sector doesn't have a monopoly on magnificent corporations.

1 Top Growth Stock to Buy and Hold Forever

This drugmaker looks unstoppable.

2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years

Great businesses are here to stay. These are two excellent examples.

3 Unstoppable Stocks to Buy Hand Over Fist in April

These stocks have exceptionally bright prospects.